Clinical Trial Update: EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD) [Phase 3]

View source ↗

Summary

Phase 3 trial update for EDG004 in adults with generalized anxiety disorder; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• EDG004

Snippet

Sponsor: Edgemont Pharmaceuticals, LLC | Conditions: Generalized Anxiety Disorder (GAD) | Phase 3 | Status: COMPLETED | Results posted: 2018-09-26